Clinical trials · Riverside–San Bernardino, CA
Small Cell Lung Cancer clinical trials in Riverside–San Bernardino
We’re tracking 205 recruiting small cell lung cancer studies with a site in or near Riverside–San Bernardino — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Riverside–San Bernardino
- NCT05394831RecruitingPhase 1/Phase 2
Study of an EGFR-targeted drug for advanced lung cancer
This trial tests a new drug (JIN-A02) in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has specific EGFR mutations. It mainly checks whether the treatment is safe and tolerable, and how the body handles the drug, with possible benefit depending on your mutation type.
Orange, CaliforniaAges 18 years+ - NCT05208762RecruitingPhase 1
PD-L1 antibody drug study for advanced lung and head/neck cancers
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Orange, CaliforniaAges 18 years+ - NCT05498428RecruitingPhase 2
Amivantamab for advanced lung cancer with EGFR mutations
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
Orange, CaliforniaAges 18 years+ - NCT06890598RecruitingPhase 3
Study of olomorasib for KRAS G12C-mutant lung cancer
This trial tests a new targeted therapy (olomorasib) combined with standard treatments for people with a specific type of non-small cell lung cancer that has a KRAS G12C mutation. Depending on the stage of your cancer, you may receive it before or after surgery, or along with chemotherapy and radiation.
Orange, CaliforniaAges 18 years+ - NCT04302025RecruitingPhase 2
Testing targeted and immunotherapy before lung cancer surgery
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
Orange, CaliforniaAges 18 years+ - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Murrieta, CaliforniaAges 18 years+ - NCT04613596RecruitingPhase 2/Phase 3
Adagrasib for KRAS G12C lung cancer, alone or with pembrolizumab
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
Laguna Hills, CaliforniaAges 18 years+ - NCT06623422RecruitingPhase 3
Vaccine plus Keytruda for lung cancer after surgery
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
Fullerton, CaliforniaAges 18 years+ - NCT07227298RecruitingPhase 1/Phase 2
Study of new drug combo for advanced lung cancer
This study tests a new combination of cancer drugs (PF-08634404 with other anticancer agents) for people with advanced non-small cell lung cancer who have not yet received any treatment for their advanced disease. It aims to see if this combination can shrink tumors or slow cancer growth.
Fullerton, CaliforniaAges 18 years+ - NCT06747585RecruitingPhase 1/Phase 2
ALE.P02 for advanced squamous cell cancers with CLDN1
This trial tests a new drug called ALE.P02 for people with advanced squamous cell cancers (like lung, head and neck, esophagus, or skin cancer) that have a certain protein called CLDN1. The drug is given alone and aims to shrink or stop the cancer.
Fullerton, CaliforniaAges 18 years+ - NCT06758401RecruitingPhase 3
Sigvotatug vedotin plus pembrolizumab for advanced lung cancer with high PD-L1
This trial tests a new combination of two study medicines for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see if adding sigvotatug vedotin to pembrolizumab works better than pembrolizumab alone.
Fullerton, CaliforniaAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Fullerton, CaliforniaAges 18 years+ - NCT07144280RecruitingPhase 3
Study of a new drug vs docetaxel for advanced lung cancer
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
Fullerton, CaliforniaAges 18 years+ - NCT06203210RecruitingPhase 3
Study of a new drug for relapsed small cell lung cancer
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
Fullerton, CaliforniaAges 18 years+ - NCT05271292RecruitingPhase 1/Phase 2
Chiauranib for advanced cancers that returned or won’t respond
This Phase 1/2 study tests chiauranib in people with advanced solid cancers (including small cell lung cancer) that have come back or no longer respond to standard treatments. It aims to find a safe dose and see whether the treatment can help shrink tumors.
Fullerton, CaliforniaAges 18 years+ - NCT07005128RecruitingPhase 3
New Drug Combo for First-Line Extensive Small Cell Lung Cancer
This trial tests adding a new immunotherapy drug (tarlatamab) to the standard first-line chemo-immunotherapy for extensive-stage small cell lung cancer. It aims to see if the combination works better than the usual treatment alone.
Fullerton, CaliforniaAges 18–99 - NCT05098132RecruitingPhase 1/Phase 2
STK-012 drug for advanced lung cancer and other tumors
This trial tests STK-012 (alone and with other treatments) in people with advanced cancers, especially non-small cell lung cancer. It may help by activating the immune system to recognize and fight the tumor.
Fullerton, CaliforniaAges 18 years+ - NCT06216301RecruitingPhase 3
Electric fields with immunotherapy and chemo for advanced lung cancer
This trial tests adding a device that delivers electric fields (Tumor Treating Fields) to standard immunotherapy and chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. It may help slow tumor growth.
Fullerton, CaliforniaAges 18 years+ - NCT07361510RecruitingPhase 3
Pumitamig vs Keytruda for advanced lung cancer with high PD-L1
This trial compares an experimental drug called Pumitamig with the approved immunotherapy drug Pembrolizumab (Keytruda) as the first treatment for advanced lung cancer that has high PD-L1 levels. The goal is to see which drug works better and has fewer side effects.
Anaheim, CaliforniaAges 18 years+ - NCT03460977RecruitingPhase 1
Mevrometostat trial for hormone-resistant prostate cancer
This Phase 1 study tests mevrometostat (PF 06821497) in people with castration-resistant prostate cancer to see if it’s safe and how the body responds to it. It may be an option if your cancer is no longer controlled by hormone therapy and your organ health tests are within limits.
Anaheim, CaliforniaAges 18 years+ - NCT06357533RecruitingPhase 3
New drug combo for advanced lung cancer with high PD-L1
This trial tests a new two-drug combination (Dato-DXd and an immunotherapy called rilvegostomig) as the first treatment for people with advanced non-squamous lung cancer who have high PD-L1 levels. The goal is to see if this combination works better than current standard options.
Anaheim, CaliforniaAges 18 years+ - NCT06801834RecruitingPhase 3
Study of sacituzumab govitecan vs. standard care for advanced small cell lung cancer
This trial tests a new drug called sacituzumab govitecan against the usual treatments for people with extensive-stage small cell lung cancer that has gotten worse after initial chemotherapy. It aims to see if the new drug helps patients live longer or have better outcomes.
Anaheim, CaliforniaAges 18 years+ - NCT05899608RecruitingPhase 3
Testing ivonescimab as first treatment for metastatic lung cancer
This Phase 3 trial tests ivonescimab as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). It may help people by improving how well the cancer responds, especially in tumors with PD-L1 activity, but you must meet specific medical and testing requirements.
Anaheim, CaliforniaAges 18 years+ - NCT07090499RecruitingPhase 1
Study of PF-08046876 for advanced solid tumors
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
Irvine, CaliforniaAges 18 years+
Hear when a new Small Cell Lung Cancer trial opens near Riverside–San Bernardino, CA
We’ll email you when one opens near Riverside–San Bernardino, CA — at most once a week, no account needed, unsubscribe anytime.
Small Cell Lung Cancer trials in other cities
Where these studies are running near Riverside–San Bernardino
Institutions with a site for the recruiting small cell lung cancer studies listed above.
- Providence Medical Foundation · 8 studies
- Providence St. Jude Medical Center · 7 studies
- University of California, Los Angeles (UCLA) · 5 studies
- City of Hope Comprehensive Cancer Center · 4 studies
- Cedars-Sinai Medical Center · 3 studies
- University of California, Irvine Medical Center / UC Irvine Health · 3 studies
- University of Southern California · 3 studies
- Valkyrie Clinical Trials · 3 studies
What taking part in a small cell lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting small cell lung cancer studies in California.
Common questions
- Are there small cell lung cancer clinical trials near Riverside–San Bernardino?
- Yes. We're currently tracking 205 recruiting small cell lung cancer studies with a site near Riverside–San Bernardino, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a small cell lung cancer study near Riverside–San Bernardino?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Riverside–San Bernardino to take part?
- Not necessarily. These studies have a site near Riverside–San Bernardino, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New small cell lung cancer studies open near Riverside–San Bernardino regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.